Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. The company also treats for solid and rare cancers; and immune system and autoimmune diseases. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Frequently asked questions
What sector does Hemogenyx Pharmaceuticals Plc (HOPHF) operate in?
Hemogenyx Pharmaceuticals Plc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Hemogenyx Pharmaceuticals Plc (HOPHF) current stock price?
As of the latest data, Hemogenyx Pharmaceuticals Plc stock price is $2.33, with a previous close of $2.33.
What is Hemogenyx Pharmaceuticals Plc (HOPHF) current market capitalization?
Hemogenyx Pharmaceuticals Plc market cap is approximately 16.07 million.
What is Hemogenyx Pharmaceuticals Plc (HOPHF) Earnings Per Share (EPS)?
The trailing EPS is -$3.14.
What is Hemogenyx Pharmaceuticals Plc (HOPHF) EBITDA?
Hemogenyx Pharmaceuticals Plc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.28 million.
Does Hemogenyx Pharmaceuticals Plc (HOPHF) pay dividends?
No. Hemogenyx Pharmaceuticals Plc does not pay a dividend.
What is Hemogenyx Pharmaceuticals Plc (HOPHF) beta (volatility) score?
Hemogenyx Pharmaceuticals Plc has a beta of 1.521, suggesting it is more volatile than the market.
